{
    "clinical_study": {
        "@rank": "119162", 
        "arm_group": [
            {
                "arm_group_label": "Rituximab+Gemcitabine+oxaliplatin (R-GemOx)", 
                "arm_group_type": "Experimental", 
                "description": "Rituximab: 375 mg/m2 IV day0, Gemcitabine 1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1(every 14 days)"
            }, 
            {
                "arm_group_label": "Gemcitabine+oxaliplatin (GemOx)", 
                "arm_group_type": "Active Comparator", 
                "description": "Gemcitabine 1g/m2 IV day 1, oxaliplatin 100mg/m2 IV day1(every 14 days)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate efficacy and safety of GemOx(Gemcitabine and\n      Oxaliplatin) combination with rituximab(R) as first-line treatment of elderly patients with\n      aggressive B cell lymphoma."
        }, 
        "brief_title": "Trial of GemOx\u00b1R Regimen in First-line Treatment of Elderly Aggressive B Cell Lymphoma", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Aggressive B Cell Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Aggression", 
                "Lymphoma", 
                "Lymphoma, B-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "Gemcitabine and Oxaliplatin(GemOx) shows effective activity in patients with relapsed\n      diffuse large-cell lymphoma and other solid tumors. Until now there is no clinical trial to\n      evaluate its role in patients with elderly aggressive B cell lymphoma. The investigators\n      therefore developed a two-weekly regimen of rituximab combined with GemOx regimen to treat\n      elderly aggressive B cell lymphoma and investigate its safety and efficacy.\n\n      Primary Outcome Measures:\n\n        -  overall response rate\n\n      Secondary Outcome Measures:\n\n        -  progression free survival\n\n        -  overall survival\n\n        -  safety and toxicity\n\n      Enrollment:  100 Study Start Date: January 2012 Primary Completion Date: Dec 2012"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically confirmed aggressive B cell lymphoma;\n\n          2. New-diagnosed and untreated;\n\n          3. Age older than 70 years or older than 60 years with ECOG PS \u2265 2;\n\n          4. Understand and voluntarily sign an informed consent form, able to adhere to the study\n             visit schedule and other protocol requirements.\n\n        Exclusion Criteria:\n\n          1. Inadequate hepatic, nephritic and cardiac function:total bilirubin, ALT, AST,Cr more\n             than two fold of upper normal level. cardiac function more than Grade II;\n\n          2. Presence of Grade III nervous toxicity with two weeks;\n\n          3. HBV virus load(HBV DNA)> 1\u00d710E5 copies/ml;\n\n          4. Concomitant malignancy other than aggressive B cell lymphoma and need to treat;\n\n          5. Concomitant with other hematologic diseases(such as leukemia,hemophilia primary\n             myelofibrosis) which investigator it unsuitable to be enrolled into this clinical\n             trial;\n\n          6. Active and severe infectious diseases;\n\n          7. Major surgery within three weeks;\n\n          8. Any potential drug abuse, medical, psychological or social conditions which may\n             disturb this investigation and assessment.\n\n          9. In any conditions which investigator considered ineligible for this study. 10. Known\n             sensitivity or allergy to investigational Product."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 7, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01670370", 
            "org_study_id": "JSPH-001"
        }, 
        "intervention": [
            {
                "arm_group_label": "Rituximab+Gemcitabine+oxaliplatin (R-GemOx)", 
                "description": "Rituximab Gemcitabine Oxaliplatin", 
                "intervention_name": "R-GemOx", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Rituximab", 
                    "Gemcitabine", 
                    "Oxaliplatin"
                ]
            }, 
            {
                "arm_group_label": "Gemcitabine+oxaliplatin (GemOx)", 
                "description": "Gemcitabine oxaliplatin", 
                "intervention_name": "GemOx", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Gemcitabine", 
                    "oxaliplatin"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Gemcitabine", 
                "Oxaliplatin", 
                "Rituximab"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Rituximab", 
            "Gemcitabine", 
            "Oxaliplatin", 
            "aggressive B cell lymphoma"
        ], 
        "lastchanged_date": "August 19, 2012", 
        "location": [
            {
                "contact": {
                    "last_name": "XiangShan Cao, M.D., Ph.D."
                }, 
                "facility": {
                    "address": {
                        "city": "ChangZhou", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "213003"
                    }, 
                    "name": "ChangZhou First People's Hospital"
                }, 
                "investigator": {
                    "last_name": "XiangShan Cao, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Min Zhou, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "ChangZhou", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "213011"
                    }, 
                    "name": "ChangZhou No.2 People's Hospital"
                }, 
                "investigator": {
                    "last_name": "Min Zhou, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Liang Yu, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "HuaiAn", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "223300"
                    }, 
                    "name": "HuaiAn First People's Hospital"
                }, 
                "investigator": {
                    "last_name": "Liang Yu, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "LEI FAN, Dr.", 
                    "phone": "86 25 6813 6034"
                }, 
                "facility": {
                    "address": {
                        "city": "NanJing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210029"
                    }, 
                    "name": "JiangSu Province Hospital"
                }, 
                "investigator": {
                    "last_name": "WEI XU, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "YanLi Xu, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "NanJing", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "210006"
                    }, 
                    "name": "NanJing First People's Hospital"
                }, 
                "investigator": {
                    "last_name": "YanLi Xu, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yun Zhuang, M.D."
                }, 
                "facility": {
                    "address": {
                        "city": "WuXi", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "214023"
                    }, 
                    "name": "WuXi People's Hospital"
                }, 
                "investigator": {
                    "last_name": "YunFeng Shen, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yan Zhu, Dr."
                }, 
                "facility": {
                    "address": {
                        "city": "ZhenJiang", 
                        "country": "China", 
                        "state": "Jiangsu", 
                        "zip": "212002"
                    }, 
                    "name": "ZhenJiang First People's Hospital"
                }, 
                "investigator": {
                    "last_name": "Yan Zhu, M.D., Ph.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Controlled Trial of GemOx\u00b1R Regimen in First-line Treatment of Elderly Aggressive B Cell Lymphoma", 
        "overall_contact": {
            "email": "fanlei_fl@yahoo.com.cn", 
            "last_name": "LEI FAN, M.D., Ph.D.", 
            "phone": "86 25 6813 6034"
        }, 
        "overall_official": {
            "affiliation": "Jiangsu Province Hospital", 
            "last_name": "WEI XU, M.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "overall response rate after treated by R\u00b1GemOx regimen", 
            "measure": "overall response rate", 
            "safety_issue": "No", 
            "time_frame": "one year"
        }, 
        "reference": [
            {
                "PMID": "18005385", 
                "citation": "L\u00f3pez A, Guti\u00e9rrez A, Palacios A, Blancas I, Navarrete M, Morey M, Perell\u00f3 A, Alarc\u00f3n J, Mart\u00ednez J, Rodr\u00edguez J. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. Eur J Haematol. 2008 Feb;80(2):127-32. Epub 2007 Nov 20."
            }, 
            {
                "PMID": "21123151", 
                "citation": "Meriggi F, Zaniboni A. Gemox: a widely useful therapy against solid tumors-review and personal experience. J Chemother. 2010 Oct;22(5):298-303. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01670370"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Jiangsu Province Hospital", 
            "investigator_full_name": "WEI XU", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "the length of time during and after treatment during which the disease being treated does not get worse.", 
                "measure": "progression free survival", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "the time frame of enrolled patients from diagnosed to death.", 
                "measure": "overall survival", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }, 
            {
                "description": "All the treatment related adverse events was evaluated according to common terminology criteria adverse events(CTCAE) version 4.0", 
                "measure": "Number of participants with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 30 days following the last dose of study drug"
            }
        ], 
        "source": "Jiangsu Province Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "WEI XU", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}